RDY:NYSE
Dr Reddy's Laboratories Ltd
US$12.90
arrow_upward
+1.18%(+0.15) 1D
US$12.90
0.00% (0.00)
bedtime시간 외 거래
휴장: 10월 15일, 오후 4시 0분 3초 GMT-4 · USD
search
모든 종목 코드
| 종목 코드 | 가격 | 변동 | 변동률(%) |
|---|
insights_autoRDY의 주요 통계 생성 중...
시가
US$12.89
고가
US$13.04
저가
US$12.84
시가총액
108.95억
평균 거래량
322.99만
거래량
1.00
배당금
0.65%
분기 배당금
US$0.02
배당락일
2026. 7. 10.
주가수익률
30.94
52주 최고가
US$15.67
52주 최저가
US$11.36
EPS
US$0.42
베타
0.30
유통 주식수
8.35억
직원 수
3만
시가
US$12.89
고가
US$13.04
저가
US$12.84
시가총액
108.95억
평균 거래량
322.99만
거래량
1.00
배당금
0.65%
분기 배당금
US$0.02
배당락일
2026. 7. 10.
주가수익률
30.94
52주 최고가
US$15.67
52주 최저가
US$11.36
EPS
US$0.42
베타
0.30
유통 주식수
8.35억
직원 수
3만
뉴스 기사
웹 소스 및 뉴스 파트너 제공
프로필
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Wikipedia
Dr Reddy's Laboratories Ltd에 관한 정보